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M~xlmal Medical  Therapy Reduces Referral for 
Cardiovascular Interventions for Patients With 
Coronary Artery Disease 
Thomas B. Gmbeya, Robyn L. De/render, Chades M. Blot/, Shmuai Ravld, 
Bernard Lown. Lown Cardiovascular Center, Brcokline, MA; Brigham and 
Women~ Hospital, Boston, MA 
We sought o assess medical therapy and outcomes among patients (PTs) 
with Coronary Artery Disease (CAD) referred for second opinions for car- 
diovascular interventions, One hundred and twanty-three consecutive PTs 
referred Io the Lown Cardiovascular Center (mean age 66 years) were fol. 
lowed prone ly ,  All were referred for second opinions as to the need for 
coronary angiOgTaphy (CA), angieplasty (PTCA), or bypass surgery (CABG), 
At referral0 nine percent of PTs had met our cdtsda fur CA, while 50% had 
undergone CA, CAD onset was occasioned by angina pecfuds in 59%; my. 
ooardlal infarction in 22%; or positive xercise stress test in t9%, Using the 
C#,nadien Cardiovascular Society Angina grading system, 28% were Class 
I, 3G% Class ti, 1% Class III, and 35% had no active angina, Left ventdc, 
uier ejection fraction averaged 59%, From reran'el to a mean follow-up of 
21 months, beta-blocker use inc:.~ased from 67% to 84%, Calcium-channel 
blocker use from 52% to 68%, and ASA use from 77% to 100%. Combination 
therapy increased from 68% to 82%. All increases were ~igniticant a p 
0.05 except long-acting nitrate use, which was un0hanged at 61%. Annual. 
ized Cardiac mortality was 1,2%; myocardial infarotion 4.9%; and unstable 
angina 9,9%. Ten percent (12) of PTs were referred for CA; 2,5% (3) PTCA; 
and 6,6% (8) underwent CABG. This prospective study suggests that a large 
fraction of CAD PTs deemed abpropdets for cardiovascular interventions are 
frequently on suboptimal medico/programs and with maximized therapy only 
infrequently need to be referred for lnvasive intervention. 
The Effect of Hydralazlne on Nitroglycerin 
- Tolerance 
John D, Pa~ker, Bernice Fan'all, John O. P~-,~er. Mount Sinai Hospital, 
Toronto, Canada; Kingston General Hosp/tal, Kingston, Canada 
Combined nitrate and hydralazina therapy reduces mortality itt CHF. Hy- 
dralazlne has been reported to prevent olerance to nit'togly~-.edn (GTN), 
possibly explaining the benefioial affects of combined therapy. This study 
examined whether concurrent hydrsiezine therapy woutd prevent the de- 
vblopment of plasma volume expansion ~nd tolerance dgdng continuous 
tr~sdsrmai GTN (TGTN) therapy. Methods: 20 normal volunteers and 18 
patients with CHF secondary to dilated cardiomyopathy (LVEF 31 4. 2%) were 
studied in a double-blind, randomized, parallel design study. Hydralazine (50 
mg TID) or matching placebo was administered for 7 days pdor to TGTN 
therapy and then continued through the rest of the study, HR, SBP and Hot. 
wore evaluated on the first day of TGTN therapy and again following 7 days 
of continuous TGTN therapy (0.6 mg/hr). Results:Tolerance tothe heart rate 
and blood pressure effects of TGTN occurred in both the normal and CHF 
group. Evidence of plasma volume expansion which persisted throughout 
TGTN treatment was seen in both groups. Hydraiaslne had no effect on 
either hemodynamlc or plasma volume responses in either group. Results in 
those receiving hydrelazine re presented below: 
D8y/hour Acute TG'IN Sustutned TGTN 
1-0800 1-1200 7-0800 ?-1200 
NL gnP 124~3 1074.4' 1R7 ~:3 122-4-4 
Hot, 0.44~ 4- 0.008 0,433 4. 0,005" 0,413 :E 0,00ST 0,422 -v O.00~t 
CHF SBP 124±2 1054.2' 129:b 2 1:23 ~2 
Hot, 0.439 ± 0,O1 0.421 4. 0.007' 0,41G :E 0,0151 0,405:t:0,011' 
Mean 4. SEM; "p < 0,05 versus 0800 hot,re, tp < 0,05 versus clay 1, ANOVA, 
Conc/usiot~, Hydroid.Ins did not prevent either plasma volume expansion 
or hemodynamln tolerance to continuous TGTN. It romalns possible that 
hydralaslue pr',/snts the development of toleran~,e to the preloed effects of 
nitrates, however It does =1oi e.ppoar to do this by preventing plasma volume 
expansion, 
~ tuman Brain N=tduratlc Peptlde (B - ' I~  
Na~rlurafl© F'eptide. BNP) In Patients With Vadous 
Calti iec Disease end In Nomml Volunteers 
HItsPR ~ I, Kenji K~r~ N~Oto M;v~arnlno, Hh~y~ I~ ,tsUO, 
Cardlovasc~.r ~ O~dm JAPAN 
Htmmn BNP (hBNP) is of cardiac odgtn but distinct fren'; haman aldal natrk 
, r ¢ ~  (A-.'y~ ~ P~:~e, ANP). We report ~ comant=,o~ 
(~)  end mekm~W farms (MFs)*n at~a =xl pmma of mue~s w~h v=mus 
c=',.t¢ ~ (CO=) (, - IO0) m~ In nom~ vokmtesm (NVe) (n - ~)  
~.~,~ a ~y  ~ ~k~mme~,~y (RUq ~ ~mP and Se~ad~ 
G-50 gel filtration. In plasma of NVS, hBNP averaged 0.35 fmoVml, about 
1/19 that of hANP (6.7 hT~l/ml); the predominant MF was y.hBNP with a 
molecular weight of 15 kDa, but distinct from human atria with hBNP-32 as 
a main MR The predominant MF of hANP is a.hANP in ,cardiac atrium and 
,z-hANP in plasma, In plasma of CD patients with congestive heart failure 
hBNP cone was about ~0-fald elevated, while that of hANP Increased only 
15-fold, compared to that of normal plasma. The predominant MF of hBNP 
of CD patients was either y-hBNP or BNP-32., which ¢O~istod of 32 amino 
acids of C.termtnai portion of ),.hBNR In right atrial appendage of patients 
with CDs the main MF of hBNP was hBNP-3;?.. Tissue corm of hBNP vat. 
led in different COs. In patients with only angina pactofls it averaged 10 
fmoVmg, but was 20-fuld higher in patients with aortic valvular disease and 
in those with complicoted acute myocardial infarction, Moreover, hBNP cone 
was higher in those with the worse cardiac function. The msufts uggest hat 
hBNP like hANP, is a circulatory hormone and may play an important role in 
the pathogen~sis of cert~n ~¢lias disorders. In addition, hBNP may have a 
processing, secretion and metabolic system that Is different from hANP, 
Mechanism of Action of a Novel Metabolically 
Active Antlanginal Agent (Trlmethazidlne) 
Dellneatml by PET 
Freny Vaghalwaga Mody, Halmich Schalbed, Kdstina Ceyle, Denis Buxton, 
Herbert Hanson, Ishtiaqae Mohiuddin, Ronald Sumid~, Brarnah Singh. West 
Los Angeles VAMC/UCLA School of Medicine, Los Angeles, California 
Tdmethazidine (TMZ) and similar agents (ranolazlna) have an antiisshamic 
effect in angina. They exert no hemedynamic effects and their mechanism of 
action is presumed to be metaboli¢. 
33 dogs with open.chest LAD branch llgation resulting in Ischamla were 
imaged with PET FDG to measure regional ischa,lliO dsk (R) and nondsk 
(NR) glucose metabolic utilization (rGMU), and with 11 -G-Acotste to measure 
K meno (decay constant) for oxidative metabolism, 20 dogs were oretroatod 
with TMZ at low (N = 10 LD) and high (N =~ IC HD) dose and c¢~nparsd to 13 
conkoI dr#ds (C), 
Microspharo myocardial blood flow (MBF), heart rats (HR) and BP were 
measured pm-occlus~on (OCC) and repeated hourly x 3 after OCC, and 
expressed as ratio of OCC/pre.OCC. There were no differences in P,/NR 
MBF between groups and within groupS for hours 1.-~3 poSt4:X~C (p = NS) 
demonstrating stable ischemla dudng PET imaging and no effect on MBF by 
TMZ. HR and BP revealed no cllange dudng OCC in C vs TMZ groups (p = 
ns). FDG dedved rGMU (mmoies/mlNgm) was increased in HD TMZ dogs 
in NR and R tissue c~mpsred to C dogs (1,16 4. 0.57 vs 0,51 4. 0,38 and 
0.43 4. 0.29 vs 0.20 4. 0.14, p < 0,05), However, rGMU corrected for NR was 
not different between groups (R/NR was 0,92 d= 1.3 vs 0,64 4. 0,66 fur C vs 
TMZ). K mend (mln -1) was not altered in NR or R tissue in C or TMZ dogs 
implying no change in o~arail oxidative metabolism, (NR = 0,13 4. 0,03 ve 
0,13 :E 0,03 & R = 0.18 d: 0.05 vs 0,17 4. 0.68, p = NSi. 
Our data verifies that his novel antialtginai gent (TMZ) does not alter he mo- 
dynamio parameters or MBR It increaseS total 01ucose t~iliization (oxidative 
and glycolyais) in myoo.a~ium without preferential increase in isshemtc tissue 
(as hypothesized). Ab,.;enco f change in total oxidative metabolism (K menD) 
suggests increased glucose utilization is prs ~ominantiy due to glycolyaiS. 
Clopldogml Oose-Rsnglng Phase II Study in 
Patients With Athescwrotlc Disease 
Bemard Boneu, on behalf of the Study Investigators. H~ital PURPAN, 
Toulouse, France 
Introducfion: Clopidograi is a novel AOP-seiectivo plate/Dr ~a l lon  in* 
hibitur which blocks the ADP.dependent activation of ptstsiet gly(~plotaln 
lib-Ilia. ]'he objectives of our study were to de/on'nine the optimal dose of 
dopldogrel, 150 patients with atheresclerotic disease and requtdn9 platelet 
antlaggregetion therapy ware enrolled in a open, mellk~nter, andomized 
study comparing 7 parallel groups: 5 groups given cJopidogrel 10, 25, 50, 
75,, 100 mg once doily; 1 group given tk:fopldlne 250 mg twice daily and a 
placebo group. Dosing was for 4 weeks, Platalet a~r~r,~a, onwas aase~ 
at baseline, day 7 and day 28, together with clink;el and laboralory moaltodng 
of t~era~t~y. 
[~ay 7" oay=8" gay ~ay  o* 
Placebo ~9.15 4" 6,37 -O.S :1:G.06 1.~:E0,14 
Ctol~dogcel 10 f~g QD 11,5:1:6,12 14.2 :E OJJ9 1.34,0,12 
Cl¢~dO~ 25 I1~ QO 29,24"4.47 28.9 "t" (~.84 1.234-0,15 
50 mg QO 2B.7 :b S,~ 2g.34.G .~0 1.50.~-0A3 
Ck~dc~Fl~ 75h'~QD 41.4:k5.11 ~.2.: ~4 1.72",'-0,27 
~-~1100 fng oO 44.1 4.10.84 37.1 ::l: 7.95 1.1~ +.0..~ 
250mQ BID 41,9+6~31 46.4 =l= 6.35 1.904.0.24 
"&  ~ ~i~u~ ¢=k:ula~ ~ 10 Oay o. Mwn, S.E.M, "l~eed~ ixo- 
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Results: Inhibition of 5/~M ADP-tnduced platefet aggr~on showed a 
trend towards a dos@relationship over lhe dose-range tested. Bleeding time 
prolongation factor never exceeded 2. Tolerance was good at all doses 
tosteoL 
Cond~:  In this muiticontor d~.e-mnge study in athe~scle~dio pa~nts, 
~ 1  demonstrated a c~mlat~ activity. The dose of 75 mg once 
daily was chosen for the phase III Interest/anal study CAPRIE (CIopid~grel 
vs, Aspidn In Patients at Risk of isohamto Events) currently on-going in over 
19,o00 patients, 
~ ~dety  of the Combination of Oral Anticoagulant 
end Antlplatelet Therapy In Cordlovascular 
Disease: A Mats*Analysis 
Fresk W.A. Vetheugt. Department of CardiolOgy, UnivemtO, Hospital 
Nijmegen, Nijmegen, The Netherlands 
Both oral anticoagulant (AC) and antipfatolet (AP) therapy are effective in 
redu~ng mortality in patients (ptS) w~h oardtovas¢~ar disease. The outcome 
Of the trials of combined AC,/AP compared to AC alone, AP alone or placebo 
is promising, but its s~ety Is a matter of con(~em, 
In the 6 published tdals of combined AC/AP directly comparing reference 
therapy (AC, AP or placate) 4,874 p~ were randomized. High intensity AC 
(AC) INR >.>. 2 5 was combined with high (>_ 500 mg asptdn op') dose AP (AP) 
in 3 ldals, and with low (_< 100 mg aspirin qd) dose AP (ap) in 2 trials. Low 
Intensity AC (a¢) INR ~ 2.5 was Combined with ap in 4 trials. Major bleeding 
(95% el): 
~,  ~s- 
~o ~o- 
E= S- 
f ~,(I,llt If' I 
[ •  indications for Lipid Management 
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~ W h e d  Should Be the Goal of LOL~Cholesterol 
Loweflng in Comn~ Patients; a Fixed Level or a 
~roent  Redu~tion? 
David Wets*s, Jus~ne Hollyer, Gilbert R. Thompson. Hartford Hospital, 
Hartford, C T; Hammersmi~ Hospital, Lanai, UK 
NCEP guidelines stipulate that LOL.~totsste~! (LDL-C) should be reduced to 
the same level in all coronary patterds, to ~ 100 mg/dl. But a recent secondary 
analysis of the 4S data showed that the decrease in LDL.-C with almvestatin 
(32-o~7%) and the do<~ease in relative risk (32~)  were o~mpera~e 
across all q~m~tiles of baseline LDL-C, despite d~emnoes in ~dat  LDL-C 
(Lancet 1995;345,1274). To test the hypothesis that the reduction in LOL-C 
cognates better with outcome than the on-treatment level of I.CL-C, we ex. 
stained the 24 control and treatment greups from the 11 ¢gnotesterol4owedng 
comna~ ang iog~ trials (FATS, SCOR, STARS, Lifestyle, MARS, CCNT, 
HARP, SCRIP, ~ ,  FHRS and PLAC-1) with quan~tative measurements 
of lesion percent diametor stenosls cllange (&%DS). Mean A%DS ranged 
from +5,8 (prog~P'~ton) to -2.5 (regression), mean on.lxial LDL-C varied 
from 86 to 242 rag/tit reel change in LDL-C ranged from +3% tO -53%. Un- 
~r  :~essio, an~s~ was I~tom~ w~ ~e groups weighted ~ng 
to their size. 
Resutts: The relationship between omffial LDL-C levels and &%OS was 
we~k; r= 0.36, p = 0.086. However, a strong mlntionship was seen between 
% change in LDL-C and &%DS t~.%DS = 3.18 + 0.071 x %&LOL-C; r = 
O.?~. p < 0 .~.  Acoordlng to the equation, ~ 44% reduction of LDL-C is 
needed to arrest comr~y progression. 
Conc/L~s/ons: Redualng LDL-d,~Olesterol by a percentage from the baseline 
level ~ to be a more reasonab~,e goal in comrade, patients than aiming 
for ~e same target svel in all. The emphasis on ta~ levets in the current 
(~l inOs seems open to question. 
A~/I~P A%ip i l lhi= AC 1¢ lip pl l¢tbo 
¢ombln~ I l tmt~gtl  mfereaee ~/e¢  
Thus, combined low intensity oral an,coagulanUIow dose aspidn therapy 
shows the lowest major bleeding (5/100 pt ym). not significantly ditterent fp.~.~ 
low Intensity oral anticoagulant l[ ~erapy alone. This combination therapy now 
undergoes large s(~e evaluation of clini~d efficacy and safety. 
~ Enhanced VuoeonsM~tlon to Coronary 
EndothellmB R~mpt~s  Actlvaffon In Experimental 
Congestive Heart Failure 
Chades R. Cannan. John C. Bumett Jr.. Amir Lemlan. ~ Clin~ 
Rochester. MN 
Thorad¢ Inferior vans cava constriction (TiVCC) ts an experimental modal of 
heart failure ~aracterlzed by a decrease in cardiac output and an Ircmase 
in plasma endothelle (ET) consentretisRs, ET, a cor011ary vesoconstifctor0 
mediates its activity through two specific receptors (ET-A and ET-B), which 
demenstmte d~fferont activity levers in pa~'~jslotogl~ mndtions. The 
eumant study was designed to test the hypothesis that e~le . fa l  heart 
fallura is char~"torized by an enhanced coronary vaso¢0~ to the ET- 
B receptors aoflvaflon. Sarafotoxin (an ET-B receptor ngo,~) ~t 2 ng4~/mfn 
was infused into the left ci=mtmlflex corona~ s#ts~j In nomlal (n = 5) and 
"nVCG (n - 5) ~mthe~ dogs. Plasma ET was alevated in me TNCC 
doge aS c~npamd to lhe Norrnal group (37 ~ 5 vs. 17 ~: 3, p < 0.05) 
~vcG 
%& CBF -~"~ 8 -31 ~4"  
%&CVR 12~B 53::1=12" 
% A CAO 1.g~0.7 2.1 -~ 1.O 
Thesa atudiss 0~m~nWate m enhemO~ mxo~y w ~  ~- 
spoese to sa turn  In exper~-c,,.-,-,;al hea~ ~ ~ is ~ iscaea~o 
to l~,e ~ '1'his StUdy ~ ,  an ~a~,~n is. om:~at'y ET-B 
mcel~o~ in s~ m~l  ~ ~,~ay  vascu~ ~ this m~i~ 
• Phyedc!an Compllanc:e W'dh National Cholesterol 
Educ~$~r= Panel Guldelimm in Patients With 
Myoeardlal Infarction 
Od Ben.Yehuda. Parul Oesal. Oardel G. Blarchatd. University of CaJifomia, 
San D~o, C~ 
Lowedng elevated LDL-Cbelestorol (LOL-C) i. patterns with documented 
CAD reduces morbidity and moflality. NGEP ggide!inss in this pepulalJon 
are ba~ed on LDL-C levels, with a largat level of < 100 rag/all. In order to 
3ssess physician compliarce with NCEP guidelinss, we ~ tt~ cam 
of all p~tients under 75 years of age dischm'ged with the dlagr<e.;is of acute 
MI in 1994 in our institution. Mean fallow.up was 9.6 :t: 0.8, months (ra~"e 
4-15), 
Of 114 patients with tha diagn~ls of acute MI, 30 (26%} had known byper 
LL~.C pdor to thalr Ml Of these only 6/30 (20%} had doomlantad LDL.C h ~ 
the t~get range on foll0w-Up. In 7/30 (23%) no therapy ~ inslituted, while in 
17/30 (57%) taq~t LOL-C level was either not acJlleved or not documented, 
Of the 84 patients (74%) witbe~ knoml I l yped i~ six had evaluation 
and therapy per NCEP gtddetinas. An tn¢0mpie~ evaluation (only total.C or 
pror~ obtained o'~eg e~te tansy) was ~ in 44t84 (S,W,,) wh,e 
16/84 (19%) had no lipld evakm~on ~ ~11, No theral~ was inatitutod In 18/84 
(21%) wha met NGEP cdtoda tot therapy. 
Overafl. only 12/114 (11%) i~tlerds were evaluated ~ to NCEP 
~ and r~d docume,'~on of~ m~tmr, t ~ .  m contres~ 
100% Of paf~ontS were ~ ASA (i) < 0.001), another ecommanded 
tbempy in ~k~ts w~, CAD. 
1"firm physk~an ¢or~ ~ NGEP guidelines in mm study was low, 
w~h most patha~ not having LDL-C bas~ ~ and themw. Greater 
ChdSl~ M, Bat~,  M. StewaR West, Su2anne M. Jaax, lylnno W. Scott, 
J. Ala~ He~l, Pe~ir H, Joi-~,~, John A. Fanlter, Antonio M. Gotto, Jr.. Bayto¢ 
corm of M~x~Ve. Hous=~ TX 
lyre ~993 NCEP reomm'oends th= de~'~ (Stop. Oie9 ~ t~ed ~ 
~p m t~ wk in ~ ad~ts w~h Clio ~ a¢~eve ~r  LDL~ go~ al 
~ . -~;~ ~ dm from the ~ ~  
:::,,::::: 
